Clinical prognostic risk analysis and progression factor exploration of primary breast lymphoma. Issue 1 (31st December 2022)

• Record Type: Journal Article
• Authors: Deng, Jili; Mi, Lan; Wang, Xiaopei; Zhu, Jun; Zhang, Chen; Song, Yuqin
• Is Part Of: Hematology. Volume 27:Issue 1(2022)
• Page Start: 1272
• Page End: 1281
• Publication Date: 2022-12-31
• Subjects: Primarybreastlymphoma -- DLBCL -- prognosis -- relapse; Blood -- Diseases -- Periodicals; Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; 616.15005
• DOI: 10.1080/16078454.2022.2150389
• Languages: English
• ISSNs: 1024-5332

Abstract

ABSTRACT : Purpose: : A primary breast lymphomais a rare form of extranodal lymphoma type. We aimed to analyze prognosticriskfactors and explore relapse factors in primary breast diffuse large B cell lymphoma (PB-DLBCL). Methods: : From November 2003 to September 2020, sixty-three patients from two medical centers newly diagnosed with PB-DLBCL patients were analyzed retrospectively. Results: : The median age was 52, and >50% of patients were post-menopausal. The international prognostics index (IPI) (0–1) was mainlyin the low-risk group (84%), and there were four patients with stage IV (6%) who had bilateral breast involvement. With a median follow-up time of 4.92 years (3.17–8.00), five-year overall survival (OS) and progression-free survival (PFS) were 78.9% and 67.1%, respectively. Univariate and multivariate analyses showed that elevated erythrocyte sedimentation rate (ESR) and B symptoms were independent adverse prognostic risk factors for OS, whereas bilateral breast involvement was unfavorable for PFS. Disease recurrence and relapse occurred in 40% (25/63) patients, mainly in the breast, followed by the central nervous system (CNS) and skin/soft tissue. Conclusion: : This is the first study to explore the prognostic risk factors and relapse factorsof PB-DLBCL in a relatively large Chinese PBL cohort. Local breast and CNS recurrence after standard R-CHOP treatment were the main issues we are facing now.